Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers

References

• Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr. Infect. Dis. J.23(Suppl. 12), S274–S279 (2004).
   PubMedGoogle Scholar
• Kaplan SL, Schutze GE, Leake JA et al. Multicenter surveillance of meningococcal infections in children. Pediatrics18, e979–e984 (2006).
   Google Scholar
• Edwards MS, Baker CJ. Complications and sequelae of meningococcal disease in children. J. Pediatr.99, 540–545 (1981).
   PubMed Web of Science ®Google Scholar
• Erickson LJ, De Wats P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin. Infect. Dis.33, 737–739 (2001).
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analyis. Lancet Infect. Dis.10, 853–861 (2010).
   PubMed Web of Science ®Google Scholar
• Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev.19, 142–164 (2006).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of vaccine-induced immunity. Clin. Infect. Dis.47, 401–409 (2008).
   PubMed Web of Science ®Google Scholar
• Harrison LH, Totter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine275, 851–863 (2009).
   Google Scholar
• Swartley JS, Marfin AA, Edupuganti S et al. Capsule switching of N. meningitidis. Proc. Natl Acad. Sci. USA94, 271–276 (1997).
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin. Infect. Dis.50(2), 184–191 (2010).
   PubMed Web of Science ®Google Scholar
• Gold R, Lepo ML, Goldschneider I et al. Clinical evaluation of group A and group C meningococcal polysaccharide vaccine in infants. J. Clin. Invest.56, 1536–1547 (1975).
   PubMed Web of Science ®Google Scholar
• Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine27(S2), 820–829 (2009).
   Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccine. FEMS Microbiol. Rev.31, 101–107 (2007).
   PubMed Web of Science ®Google Scholar
• Simpkines DB, Wood N, Jelfs J et al. Modern trends in mortality from meningococcocal disease. Pediatr. Infect. Dis. J.28, 1119–1120 (2009).
   Google Scholar
• CDC. Updated recommendations for use of meningococcal conjugate vaccines – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep.60, 72–76 (2011).
   PubMedGoogle Scholar
• Rennels M, King J Jr, Ryall R et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J.23, 429–435 (2004).
   PubMed Web of Science ®Google Scholar
• Keyserling H, Pina M, Hou V, Bhassily E, Reinhardt A. Immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135 (MCV-4) in 9 to 15 month olds. Programs and Abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, Canada (2006) (Abstract 640).
   Google Scholar
• Snape MD, Perrett KP, Ford KJ et al. Immunogenicity of a tetravalent meningococcal conjugate vaccine in infants: a randomized trial. JAMA299, 173–184 (2008).
   PubMed Web of Science ®Google Scholar
• Perrett KP, Snape MD, Ford KJ et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal vaccine infants. Pediatr. Infect. Dis. J.28, 186–193 (2009).
   PubMed Web of Science ®Google Scholar
• Nolan T, Lambert S, Roberton D et al. A novel combined Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa–HBV–IPV and conjugate pneumococcal vaccines in infants. Vaccine25(51), 8487–8499 (2007).
   PubMed Web of Science ®Google Scholar
• Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y–tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12 to 18 months of age. Hum. Vaccin.6, 640–651 (2010).
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody. Vaccine23, 2222–2227 (2005).
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. The role of humoral antibodies. J. Exp. Med.129, 1307–1326 (1969).
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol.10, 780–786 (2003).
   PubMedGoogle Scholar
• Roush SW, Murphy TV. Vaccine Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA298, 2155–2163 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis.149(6), 1034–1035 (1984).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis.147(6), 1100 (1983).
   PubMed Web of Science ®Google Scholar
• Marchant CD, Miller JM, Marshall GS et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y–tetanus toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J.29, 48–52 (2010).
   PubMedGoogle Scholar
• Marshall GS, Marchant CD, Blatter M et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y–tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age. Pediatr. Infect. Dis. J.29, 469–471 (2010).
   PubMedGoogle Scholar
• Nolan T, Richmond P, Marshall H et al. Immunogenicity and safety of an investigational combined Haemophilus influenzae type B–Neisseria meningitidis serogroups C and Y–tetanus toxid conjugate vaccine. Pediatr. Infect. Dis. J.30, 190–196 (2011).
   PubMedGoogle Scholar
• Bryant K, Marshall G, Marchant C et al. Immunogenicity and safety of H. influenzae type b–N. meningitidis C/Y conjugate vaccine in infants. Pediatrics127(6), e1375–e1385 (2011).
   PubMedGoogle Scholar
• Bryant KA, McVernon V, Marchant CD et al. Immune response to measles, mumps, rubella (MMR) and varicella (V) vaccine coadministered with a fourth dose of Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y (HibMenCY) vaccine in toddlers. Programs and Abstracts of the Pediatric Academic Societies’ Annual Meeting. Vancouver, Canada (2010) (Abstract 2861.468).
   Google Scholar
• Bryant K, Marshall GS, Marchant CD et al.Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY) was immunogenic with an acceptable safety profile in two Phase 3 trials. Programs and Abstracts of the 44th National Immunization Conference. Atlanta, GA, USA (2010) (Abstract 22739).
   Google Scholar
• Marshall GS, Mesaros N, Aris E, Marchant CD, Blatter M, Miller JM. Persistence of immunity three years after an investigational Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y–tetanus toxoid (HibMenCY–TT) conjugate vaccine. Programs and Abstracts of the 45th National Immunization Conference. Washington, DC, USA (2011) (Abstract 25219).
   Google Scholar
• Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N. Engl. J. Med.342(3), 219–220 (2000).
   PubMed Web of Science ®Google Scholar